JANTOVEN Drug Patent Profile
✉ Email this page to a colleague
When do Jantoven patents expire, and when can generic versions of Jantoven launch?
Jantoven is a drug marketed by Upsher Smith Labs and is included in one NDA.
The generic ingredient in JANTOVEN is warfarin sodium. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the warfarin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jantoven
A generic version of JANTOVEN was approved as warfarin sodium by BARR on March 26th, 1997.
Summary for JANTOVEN
Recent Clinical Trials for JANTOVEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nicholas Carlson | Phase 4 |
Danish Heart Foundation | Phase 4 |
Daiichi Sankyo, Inc. | Phase 1 |
Pharmacology for JANTOVEN
Drug Class | Vitamin K Antagonist |
Mechanism of Action | Vitamin K Inhibitors |